NEW YORK, February 24, 2017 /PRNewswire/ --
E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound care, announced today it has received marketing approval for the Company's patented Bio-electrical Signal Therapy Device ("BST Device") in Israel from the Israeli Ministry of Health. The Accessories and Medical Devices Registration (AMAR) is granted in order to secure safety and efficacy for medical devices used in Israel. BST is a breakthrough novel electrotherapy for the non-invasive treatment of hard-to-heal chronic wounds.
E-QURE intends to immediately begin marketing efforts in Israel by activating its signed distribution agreement with Chemipal Ltd, which was concluded last year and was pending AMAR approval. The Israeli advanced wound care market size is estimated at $250 million, with no electrical device on the market prior to the BST's approval.
E-QURE intends to start commercial activity in the private healthcare market, and has filed for including BST treatment in Israel's approved National Health Basket, the national healthcare reimbursement system.
"Israel is going to be our commercial pilot sales market. Taking advantage of this small but lucrative wound care market, we intend to build revenues and implement sales techniques that will help us in other markets around the world," stated Ron Weissberg, Chairman of E-QURE Corp.
E-QURE Corp (OTCQB: EQUR) is a leader in medical devices for the treatment of advanced wound care. E-QURE's breakthrough patented Bioelectrical Signal Therapy (BST) Device is the only method in the world to non-invasively close and heal chronic wounds and ulcers. Current methods of chronic wound treatment at best treat or reduce the wound, but none consistently heal or cure it. The BST Device not only cures wounds, it does so faster, at lower cost, and with more convenience to the patient and the healthcare system. The BST Device has received regulatory approval in Europe and Israel, and is expected to launch in Q1 - Q3 2017 in Israel and Argentina, where approval is pending. E-QURE plans to begin its pivotal U.S. FDA trial in the first quarter of 2017. The Company's pipeline includes additional proprietary wound care products in development.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss the potential of E-QURE BST device to treat wounds. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE Corp. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE reports filed from time to time with the Securities and Exchange Commission.
Media Contact: E-QURE Corp +972-8-916-7333 Info@e-qure.com
SOURCE E-QURE Corp.
Subscribe to our Free Newsletters!
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic ...
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...View All